{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-101377","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.905542+00:00","generated_at":"2026-06-10T14:57:20.582334+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Black Diamond Therapeutics appoints Mark Velleca as CEO; David Epstein steps down","bullets":["David M. Epstein separated as President and CEO effective Sept 15, 2023; remains on board until 2024 annual meeting.","Mark Velleca, M.D., Ph.D. appointed President and CEO effective Sept 16, 2023; continues as Chairman.","Velleca receives $620K base salary, 55% target bonus, and stock options for 1,000,000 shares.","Samarth Kulkarni appointed Lead Independent Director; Audit/Nominating committees unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-101377","json":"https://secwatch.observer/filing/0001104659-23-101377.json","markdown":"https://secwatch.observer/filing/0001104659-23-101377.md","text":"https://secwatch.observer/filing/0001104659-23-101377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923101377/0001104659-23-101377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923101377/tm2326304d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:57:20.582334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33e86500a6","claim":"Samarth Kulkarni was appointed as Lead Independent Director at Black Diamond Therapeutics, Inc..","evidence_excerpt":"The Board appointed Samarth Kulkarni, Ph.D. to serve as the Lead Independent Director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923101377/0001104659-23-101377-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"},{"claim_id":"4eecb961ee","claim":"David M. Epstein departed as President and Chief Executive Officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"On September 18, 2023, Black Diamond Therapeutics, Inc. (the “Company”) announced that it separated with David M. Epstein, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, in each case, effective as of September 15, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923101377/0001104659-23-101377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"7422169f4c","claim":"Mark A. Velleca was appointed as President and Chief Executive Officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Effective September 16, 2023, the Board appointed Mark A. Velleca, M.D., Ph.D. as President and Chief Executive Officer and principal executive officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923101377/0001104659-23-101377-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}